Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JX-594 |
Synonyms | |
Therapy Description |
Pexastimogene devacirepvec (JX-594) is a thymidine kinase-inactivated oncolytic vaccinia virus expressing human GM-CSF, which selectively infects transformed cells and induces cell death (PMID: 22186794). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JX-594 | Pexastimogene devacirepvec|JX594|Pexa-vec|TG-6006 | Pexastimogene devacirepvec (JX-594) is a thymidine kinase-inactivated oncolytic vaccinia virus expressing human GM-CSF, which selectively infects transformed cells and induces cell death (PMID: 22186794). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02562755 | Phase III | JX-594 Sorafenib | Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone | Completed | USA | NZL | ITA | ISR | GBR | FRA | DEU | CAN | AUS | 7 |